Journal Mobile Options
Table of Contents
Vol. 60, No. 4, 2001
Issue release date: June 2001

Single-Agent Gemcitabine Is Active in Previously Treated Metastatic Breast Cancer

Spielmann M. · Llombart-Cussac A. · Kalla S. · Espié M. · Namer M. · Ferrero J.-M. · Diéras V. · Fumoleau P. · Cuvier C. · Perrocheau G. · Ponzio A. · Kayitalire L. · Pouillart P.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background: This phase II study was designed to assess the efficacy and safety of gemcitabine in patients with metastatic breast cancer (MBC) previously treated with an anthracycline- or anthracenedione-containing regimen as first-line therapy for metastatic disease. Patients and Methods: Forty-seven patients with MBC were enrolled in five French centers. Patients were eligible if they had received one prior chemotherapy regimen with an anthracycline or anthracenedione for metastatic disease, if they had responded to that prior regimen, and if they had relapsed at least 6 months after the first response. Fifteen patients received more than one prior anthracycline regimen; thus, gemcitabine was third-line therapy for 30% of patients. Gemcitabine 1,200 mg/m2 was administered as a 30-min intravenous infusion on days 1, 8, and 15 of a 28-day cycle for a maximum of eight cycles after the best response was obtained. Results: Objective responses were seen in 12 of 41 assessable patients (4 complete responses and 8 partial responses), for an objective response rate of 29% (95% confidence interval, 16–46%). The median response duration was 8.1 months (range: 2.5–27.4 months). Serious hematological toxicity was minimal, with grade 4 neutropenia in 2% of the patients (no neutropenic fever), grade 3 neutropenia in 28% of the patients, and grade 3 thrombocytopenia in 6% of the patients. Among the nonhematological toxicities, asthenia was the most common. Conclusions: Gemcitabine given at this dose and schedule is a well-tolerated treatment with definitive antitumor activity in pretreated MBC patients. This result warrants future exploration of the use of gemcitabine as a single agent and in combination in patients with MBC.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Greenberg PA, Hortobagyi GN, Smith TL, et al: Long-term follow up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996;14:2197–2205.
  2. Henderson IC, Harris JR: Breast diseases. Principles in the management of metastatic disease, integration of local and systemic therapies; in Harris JR, Hellman S, Henderson IC, et al (eds). Philadelphia, Lippincott, 1991, pp 547–558.
  3. A’Hern RP, Smith IE, Ebbs SR: Chemotherapy and survival in advanced breast cancer: The inclusion of doxorubicin in Cooper type regimens. Br J Cancer 1993;67:801–805.
  4. Henderson IC: Breast diseases. Principles in the management of metastatic disease, chemotherapy for metastatic disease; in Harris JR, Hellman S, Henderson IC, et al (eds). Philadelphia, Lippincott, 1991, pp 604–665.
  5. Crown J: A review of efficacy and safety of docetaxel as monotherapy in metastatic breast cancer. Semin Oncol 1999;26:5–9.
  6. Gianni L, Munzone E, Capri G, et al: Paclitaxel in metastatic breast cancer: A trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. J Natl Cancer Inst 1995;87:1169–1175.
  7. Plunkett W, Huang P, Searcy CE, et al: Gemcitabine: Preclinical pharmacology and mechanisms of action. Semin Oncol 1996;23(suppl 10):3–15.
  8. Barton-Burke M: Gemcitabine: A pharmacologic and clinical overview. Cancer Nurs 1999;22:176–183.
  9. Fossella FV, Lippman SM, Shin DM, et al: Maximum-tolerated dose defined for single agent gemcitabine: A phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer. J Clin Oncol 1996;15:310–316.
  10. Carmichael J, Possinger K, Phillip P, et al: Advanced breast cancer: A phase II trial with gemcitabine. J Clin Oncol 1995;13:2731–2736.
  11. Blackstein M, Vogel CL, Ambinder R, et al: Phase II study of gemcitabine in patients with metastatic breast cancer (abstract 664). Eur J Cancer 1997;33(suppl 8):S149.
  12. Possinger K: Gemcitabine in advanced breast cancer. Anticancer Drugs 1995;6(suppl 6):55–59.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50